FDA Clears GSK's Nelkarmi, Second Asset from $10.6B Nuvalent Deal
FDA grants accelerated approval to GSK's neladalkib (Nelkarmi) for ALK-positive NSCLC, 10 days ahead of the Nov. 27 action date, on ALKOVE-1 data showing 49% ORR post-Alecensa.
TAG C-9698 · 465 words on the filing

Summary of findings
- FDA granted accelerated approval to neladalkib (Nelkarmi) 10 days ahead of the Nov. 27 action date
- Approval stems from GSK's $10.6 billion acquisition of Nuvalent Bio closed in June
- ALKOVE-1 (700 patients) showed 49% ORR after Alecensa-only exposure and 32% after two or more prior ALK TKIs
- Intracranial ORR reached 55% in patients with measurable CNS metastasis post-Alecensa
- Phase 3 ALKAZAR is testing Nelkarmi in TKI-naive ALK-positive NSCLC and other solid tumors
The FDA has granted accelerated approval to neladalkib, GSK's ALK-targeted tyrosine kinase inhibitor, for previously treated ALK-positive non-small cell lung cancer — the second regulatory win from the company's $10.6 billion acquisition of Nuvalent Bio. The clearance arrived 10 days ahead of the November 27 target action date, GSK announced Tuesday.
The approval covers patients with advanced disease whose unresectable tumors have progressed on prior lines of treatment. GSK will market the drug under the brand name Nelkarmi. As with all accelerated approvals, the company must verify clinical benefit in a confirmatory study to keep the designation.
Where does Nelkarmi sit in the GSK portfolio?
The Nuvalent takeover, closed in June for $10.6 billion, ranks among the industry's largest deals this year. It delivered two lead NSCLC assets:
- Zidesamtinib, a ROS1 inhibitor approved by the FDA in July as Jideytro;
- Nelkarmi, the ALK inhibitor approved this week.
Nuvalent also brought NVL-330, a HER2 blocker now in Phase 1 development for NSCLC, giving GSK a third targeted oncology candidate from the transaction.
What did ALKOVE-1 deliver?
The filing rested on the Phase 1/2 ALKOVE-1 study, which enrolled 700 patients with ALK-positive solid tumors. Objective response rate, one of the trial's primary endpoints, split by prior therapy:
- 49% ORR in patients whose only prior ALK TKI exposure was Genentech's Alecensa;
- 32% ORR in patients who had received at least two prior lines of ALK TKI therapy.
GSK designed Nelkarmi to address drug resistance and to treat NSCLC that has spread to the brain. The intracranial data support that intent: among ALKOVE-1 patients with measurable CNS metastasis whose only prior ALK TKI was Alecensa, intracranial ORR reached 55%.
The drug previously held the FDA's breakthrough therapy designation, reserved for therapies treating serious diseases with early evidence of substantial improvement over available options.
What is the tolerability profile?
Five percent of treated patients permanently discontinued Nelkarmi due to adverse reactions, with liver toxicities the most common cause of discontinuation. The prescribing information carries warnings and precautions for hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation and embryo-fetal toxicity. Other frequently reported side effects include constipation, muscle or bone pain, edema and fatigue.
The safety profile will shape positioning against the entrenched ALK TKI class, where physicians weigh persistence against managed toxicities.
What happens next?
GSK is running the Phase 3 ALKAZAR study for Nelkarmi in TKI-naive ALK-positive NSCLC patients and other solid tumors. That trial carries dual weight: it can both satisfy the confirmatory obligation attached to the accelerated approval and extend the label into the earlier, larger treatment-naive population.
For pipeline planners, the question is whether ALKAZAR converts this week's second-line clearance into front-line competition.
via FDA industry wire (Google News) (Source)
More from Olivia Hart
Show full bio
Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
13 articles
Linked filings
- C-6506
- K-5457
- V-1848
- C-7994
- E-6700